The biotech footprint has been exponentially expanding around the globe and no division has increased more feverishly in recent years than the Cell and Gene Therapy (CGT) space. This is where partnering with an experienced CDMO can de-risk your path to said critical milestones and provide that seamless transition from development to the clinic and into both a regional and global commercial supply. Joe Garrity at Lonza Cell and Gene Technologies outlines the importance of partnering with an experienced CDMO.
Extract:
CGT CDMO Partnering: More than just Manufacturing
The biotech footprint has been exponentially expanding around the globe and no division has increased more feverishly in recent years than the Cell and Gene Therapy (CGT) space. With hundreds to thousands of products in the pre-clinical and clinical phases, the industry has improved in both a quantitative and qualitative way, but it has also exposed numerous pain points that have created critical bottlenecks affecting the ability for a smooth transition into clinic and subsequently to market. With the CGT space being at a critical inflection point, the current ways of working to develop, manufacture, and deliver products and treatments to customers (and subsequent patients) results in a greater need to access GMP manufacturing capacity for meeting clinical and commercial demand, particularly for small biotech firms developing cell and gene therapies. With continuing pressure coming from accelerated timelines and milestone deliveries without sacrificing quality, many of these firms lack the expertise, facilities, and supply networks needed to quickly scale up for clinical or commercial development. This is where partnering with an experienced CDMO can de-risk your path to said critical milestones and provide that seamless transition from development to clinic and into both a regional and global commercial supply.
While the cell therapy and gene therapy field has been around in some way, shape, or form since the 1950s and 1970s respectively, only in recent years has the industry really started to take off. Over those previous decades of predominately research and development, the landscape has morphed from viral vector to allogeneic to autologous and everywhere in between. Today’s landscape is a healthy mix of all three modalities and is expected to continue as such as depicted in Table 1 (as shown in the downloaded PDF).
Click the download button below to read the complete version of ‘CGT CDMO Partnering: More than just Manufacturing’ by Joe Garrity at Lonza Cell and Gene Technologies
